Tritace in renal disease

Tritace (ramipril) is now licensed for the treatment of incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, or manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥3g/day.

View Tritace drug record

Further information: Sanofi-aventis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Drug shortages - live tracker

Drug shortages - live tracker

Added: co-fluampicil.
Use our constantly updated...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury